Search

Your search keyword '"Gifford, Andrew J"' showing total 244 results

Search Constraints

Start Over You searched for: Author "Gifford, Andrew J" Remove constraint Author: "Gifford, Andrew J"
244 results on '"Gifford, Andrew J"'

Search Results

1. The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

2. The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis

4. A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

5. Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes

7. Precision-guided treatment in high-risk pediatric cancers

10. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

15. Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

16. Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

17. Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

18. Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

19. Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

20. High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

21. Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas

22. Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial

23. Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo

24. Data from Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression

25. Supplementary Figure S4 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

26. Supplementary Information from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

27. Supplementary Figure Legends from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

28. Supplementary Video S1 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

29. Supplementary Figures from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

30. Supplementary Figure S1 F-I from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

31. Supplementary Figure S5 F-H from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

32. Supplementary Figure S3 F-G from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

33. Supplementary Figure S6 A-F from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

34. Supplementary Materials from Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression

35. Supplementary Figure S2A-C from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

36. Supplementary Figure S6 G-K from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

37. Supplementary Tables 1-5 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

39. Improved local diagnosis of focal hyperinsulinism in the COVID‐19 era by interstate radiopharmaceutical transport

40. Additional file 1 of A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

41. A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

46. The important role of routine cytopathology in pediatric precision oncology

47. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

49. DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM

Catalog

Books, media, physical & digital resources